In part 3 of this Exclusive Interview, Dr. Ray Kausik talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 convention in San Diego, CA about PCSK9 effects on the heart and the work toward lowering the risk of cardiovascular death.
Ray Kausik, MB, ChB, MD, is Professor of Public Health in the Department of Public Health and Primary Care at Imperial College London as well as Honorary Consultant Cardiologist at the Imperial College NHS Trust.
Transcript of this video segment:
Freed: Lowering their risk is great and that’s what really life is about, lowering your risk for dying. Do we have numbers as to how much were lowering the risk for death?
Kausik: In terms of the cardiovascular trials done so far, there is only one trial done with a monoclonal where we basically know that you reduce for every 39 mgs per deciliter, you reduce risk by about 22% over about 18 percent for 39 mgs per deciliter difference maintained over 2 years. Because it’s such a short period of time of treatment, that’s not enough to reduce the risk of death. You reduce the risk of non-fatal MIs and strokes. We have another trial coming out next year called Odyssey Outcomes, which will have over three years of follow-up and it’s in a much higher patient population. It will be interesting to see if we will get more of a trend towards a reduction in mortality with longer follow up, but we’re expecting, with longer treatment, that you will see more and more benefits because if treatment is relatively short, it’s too short to actually see these large differences. It’s about lifelong treatment and the trials done today have been relatively short.
To view other segments in this video series:
Part 2: PCSK9 Effect On HDL Goal Levels